Sydney, May 20, 2016 - (ABN Newswire) - Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.
To view the research report, please visit: http://abnnewswire.net/lnk/0037ZFBJ
WEB: Potential Japan Licence Deal a STEP Closer
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a patented portfolio of therapies to address significant unmet medical needs in the human and animal health markets. The company has a number of therapies targeting human conditions in various stages of development including two products in first-in-human Phase I trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions; RGSH4K is a human autologous personalised therapeutic cancer vaccine to treat a wide range of cancer types.
To view the research report, please visit: http://abnnewswire.net/lnk/0037ZFBJ
WEB: Potential Japan Licence Deal a STEP Closer
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a patented portfolio of therapies to address significant unmet medical needs in the human and animal health markets. The company has a number of therapies targeting human conditions in various stages of development including two products in first-in-human Phase I trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions; RGSH4K is a human autologous personalised therapeutic cancer vaccine to treat a wide range of cancer types.
